| Project/Area Number |
26860497
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Niigata University |
|---|
Principal Investigator |
Kamimura Hiroteru 新潟大学, 医歯(薬)学総合研究科, 特任助手 (40706420)
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2014: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
|
|---|
| Keywords | B型慢性肝炎 / 肝細胞癌 / ｓMICA / 抗MICA抗体 / MICA / sMICA / 慢性B型肝炎 / 抗腫瘍抗体 / ADCC / CDC / 膵癌 |
|---|
| Outline of Final Research Achievements |
The aim of this study is investigating the possibility of anti-MICA antibody being self antibody as the anti cancer antibody as hepatocellular carcinoma.
We performed revelation of MICA and measured the anti-MICA antibody for LABScreen MICA Single Antigen tests from the plasma from chronic hepatitis origin, hepatocellular carcinoma.Moreover,although the HLA typing inspection was conducted by type SSO corresponding to serum, the same thing as self-allele did not exist. About the anti-MICA antibody,possibility that it was not the self-antibody which appeared as an antitumor antibody was taken into consideration. We performed the concentration of sMICA simultaneously with anti-MICA antibody ｍeasurement.It has become apparent that the concentration of sMICA would serve as a carcinogenic prediction marker after nucleotide analogue medication by multivariate studies.
|
